Our Team

The Esolate team is a list of proven professionals who provide the necessary expertise, experience, passion and vision for success.

 

Hardin Jackson, Chief Executive Officer

Hardin brings years of experience in start-ups and new venture development across industrial, manufacturing, technology and cannabis market verticals. In addition to significant experience in setting business strategy for all market verticals, Hardin manages the Canadian API and formulations operations spearheading production and process design teams across the group’s cannabis, wellness, psychedelic, and pharmaceutical initiatives.

Hardin bridges the links between strategy, business development, client relations, and scientific innovations.

Mark Goliger, President and Chief Strategy Officer

Mark leads the group’s commercialization and licensing initiatives and consummates relationships with our partners across our businesses.

Mark has been a key figure in the cannabis market vertical. In his most recent position as CEO of Meta Growth, Mark was instrumental in starting businesses in medicinal cannabis distribution in Canada. Upon legalization, Meta grew into recreational retail cannabis, becoming an industry leader with a footprint of 35 outlets across five provinces. Through his direction as CEO, revenues grew from $1.2m to greater than $55m. As a public traded company, Meta grew to over 400 employees and successfully merged to become the largest cannabis retailing group in Canada.

Julian Bryson, Chief Investment Officer

Julian is responsible for the group’s IP development, licensing strategy and EU and UK business development as well ensuring the transatlantic operations of the Group run smoothly on the commercial as well as the scientific teams level.

Julian previously acquired the worldwide rights, and subsequently patented, a novel medical devices sterilization technology. As a result, Julian founded medical systems development specialist Sterilox Technologies, which listed on the London Stock Exchange as life sciences specialist Puricore plc, valued at £100m. The business was subsequently acquired by Cantel Medical Corp (NYSE:CMD).

Jinhee Oh, MSc. Chief Science Officer

Jinhee overseas the Esolate formulations development, as well as leading bespoke client product design for Esolate licensees across formulation portfolio.

Jinhee is a leading expert in the proprietary technology underpinning the Esolate offering and IP. She is an expert in the field of applied chemical engineering and cannabinoid research, and is responsible for Esolate’s chemical and process engineering design.

Previously instrumental in the design, development and production of cannabis extraction facilities, laboratories, post processing plant technologies and CPG formulations design. Jinhee was formerly research division lead at LG Chem and is an inventor on LG patents. She acted as a Commissioned Research Scientist at Korea Institute of Science and Technology.

Devin Machin MSc., Biochemical Engineering Officer

Devin is responsible for the development of Esolate’s cannabinoid formulations portfolio at the pure chemistry level, leading the Company’s proprietary formulation research and development throughout the biochemical research phase, as well as designing and running technical research for in-house and client applied product solutions

Devin is an alumni of the renowned research team at the Department of Chemical and Biochemical Engineering at University of Western Ontario, and an expert in chemical synthesis of cannabinoids and derivative formulations.

Darrell Lowes, Product Development and Optimization

As an established CPG entrepreneur Darrell plays a key role in coordinating product development projects.  This includes resolving issues of technical feasibility, design optimization, and production issues.  His extensive knowledge in input requirements and methodologies post processing has helped Esolate fine-tune the broad range in formulations for targeted product solutions and increased end product quality.

 

Michael Saliken, Legal Counsel - BLG

Michael is a partner at Borden Ladner Gervais LLP, where he focuses on commercial transactions and corporate governance for issuers, investment banks and private equity firms. Michael sits on the steering committee of BLG's Psychedelics and Cannabis Focus Group and is a board member and advisor to various businesses and NPOs.

Dr Andrew Saich, Pharmaceutical Development Advisor

Pharmaceutical Development Esolate.

Andrew provides input and guidance to the medical development initiatives at Esolate 

Over 20+ years in the pharmaceutical industry, Andrew created and lead the GW Pharmaceuticals ex-US Medical organization in preparation for the launch of Epidyolex. GW Pharma is the world leader in the development of cannabinoid medicines and Andrew was a senior member of the International Leadership team, the Clinical Development Committee and the Corporate Drug Safety team.

Andrew was Chief Medical Officer of Senzer Pharmaceuticals with responsibility for the clinical development and drug safety for both cannabinoid and non-cannabinoid inhaler programs.

Dr Natasha Murataeva PhD, Chemical Biology Officer

Natasha applies her dozen years’ experience in cannabis pharmacology to running Esolate’s cellular biology research initiatives. Natasha is an expert in the molecular mechanisms of cannabinoid receptors in relation to the cell biology of living organisms, as well as cell auto-reparation mechanism responses to phyto-, endo- and synthetic-cannabinoids. Natasha's leads the initiation of novel product development research programs for Esolate partners and licensees, across the consumer and controlled drug development portfolios, utilizing the unique Esolate technology platform.  Dr Murataeva received her MSc in Science and Biology and her PhD in Neuroscience at the University of Indiana, Bloomington, US